Lupin Limited (NSE:LUPIN)
2,055.30
+2.40 (0.12%)
Nov 14, 2025, 3:30 PM IST
Lupin Revenue
Lupin had revenue of 70.48B INR in the quarter ending September 30, 2025, with 24.23% growth. This brings the company's revenue in the last twelve months to 247.51B, up 15.49% year-over-year. In the fiscal year ending March 31, 2025, Lupin had annual revenue of 227.08B with 13.48% growth.
Revenue (ttm)
247.51B
Revenue Growth
+15.49%
P/S Ratio
3.79
Revenue / Employee
10.31M
Employees
24,006
Market Cap
937.68B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 227.08B | 26.97B | 13.48% |
| Mar 31, 2024 | 200.11B | 33.69B | 20.25% |
| Mar 31, 2023 | 166.42B | 2.36B | 1.44% |
| Mar 31, 2022 | 164.05B | 12.43B | 8.19% |
| Mar 31, 2021 | 151.63B | -2.12B | -1.38% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 549.64B |
| Aurobindo Pharma | 325.14B |
| Cipla | 279.66B |
| Zydus Lifesciences | 244.94B |
| Apollo Hospitals Enterprise | 232.65B |
| Mankind Pharma | 135.46B |
| Glenmark Pharmaceuticals | 134.56B |
| Alkem Laboratories | 133.04B |
Lupin News
- 2 days ago - Lupin unveils dedicated oncology block at Vizag to boost global CDMO capabilities - Business Upturn
- 4 days ago - Lupin share: Morgan Stanley maintains equalweight, Jefferies buy; brokerages see up to 16.8% upside on strong US business and margin guidance - Business Upturn
- 6 days ago - Lupin Ltd (BOM:500257) Q2 2026 Earnings Call Highlights: Record Revenue and Strategic Growth ... - GuruFocus
- 6 days ago - Lupin’s Pune Bioresearch Centre clears US FDA inspection with zero observations - Business Upturn
- 6 days ago - Q2 2026 Lupin Ltd Earnings Call Transcript - GuruFocus
- 21 days ago - Lupin launches Authorized Generic Version of Ravicti Oral Liquid in the U.S. - Business Upturn
- 5 weeks ago - Lupin launches strategic partnership program to expand reach of PrecisionSphere long-acting injectable platform - Business Upturn
- 5 weeks ago - Lupin shares rally over 3% after announcing $250 million investment in new manufacturing plant - Business Upturn